IMMUNIC director granted 25,370 stock options
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options that can convert into 25,370 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options that can convert into 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and after this award Phillips holds 25,370 stock options directly.
Insider Trade Summary
Grant/Award: 25,370 shares
Grant/Award
1 txn
Insider
PHILLIPS BARCLAY A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 25,370 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 25,370 contracts (Direct)
Footnotes (1)
- F1. The option vests in monthly increments over a period of one year from the grant date.
Key Figures
Options granted: 25,370 options
Exercise price: $14.80 per share
Expiration date: July 5, 2036
+2 more
5 metrics
Options granted
25,370 options
Stock option award to director Barclay A. Phillips
Exercise price
$14.80 per share
Conversion price for IMMUNIC common stock under options
Expiration date
July 5, 2036
Option term end date
Underlying shares
25,370 shares
IMMUNIC common stock underlying the options
Post-grant derivative holdings
25,370 options
Total options held after transaction
Key Terms
Stock Option, Grant, award, or other acquisition, exercise price, vests in monthly increments, +1 more
5 terms
Stock Option financial
"security_title: "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "14.8000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in monthly increments financial
"The option vests in monthly increments over a period of one year"
expiration date financial
"expiration_date: "2036-07-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did IMMUNIC (IMUX) report for Barclay A. Phillips?
IMMUNIC reported that director Barclay A. Phillips received a grant of stock options covering 25,370 shares of common stock. This is a compensation-related award, not an open-market share purchase or sale, and reflects equity-based pay rather than a traded transaction.
What are the key terms of Barclay A. Phillips' new IMMUNIC (IMUX) stock options?
The granted stock options allow purchase of 25,370 IMMUNIC common shares at an exercise price of $14.80 per share. They expire on July 5, 2036, giving a long exercise window typical for director or executive incentive compensation packages.
How do the IMMUNIC (IMUX) stock options granted to Barclay A. Phillips vest?
The options vest in monthly increments over one year from the grant date. This means portions become exercisable each month during the first year, aligning Phillips’ potential equity ownership progressively with his ongoing board service.
How many IMMUNIC (IMUX) stock options does Barclay A. Phillips hold after this grant?
After the reported grant, Phillips directly holds 25,370 stock options linked to IMMUNIC common stock. These options represent his reported derivative position in the filing and become exercisable over time as monthly vesting occurs during the first year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates